Neuroscience

#Interview #Mental health #Neuroscience #Precision psychiatry #Psychiatry #Psychiatry Consortium #Target identification #Target validation

Target validation in psychiatry: addressing unmet therapeutic needs

The Psychiatry Consortium and the British Neuroscience Association recently published their ‘Guiding Principles for Robust Target Validation in Psychiatry’. Dr Ekta Patel, Psychiatry Consortium Partnership Manager, spoke to DDW’s Diana Spencer about how the guide can help researchers to create a target validation package and the need for new… Read More

#Exclusive Content

AI brain
#AI / data analytics / healthtech / informatics #ALS #Biotechnology #Clinical trials #Drug discovery #Genomics

AI-driven biotech initiates Phase I trial for ALS drug 

Verge Genomics, a clinical-stage, tech-enabled biotechnology company using artificial intelligence (AI) and human data to transform drug discovery, has announced today that the first subject has been dosed in a Phase I clinical trial of VRG50635 for amyotrophic lateral sclerosis (ALS).  VRG50635 is a small molecule inhibitor… Read More

#News

Magic mushrooms
#Depression #Mental health #Psilocybin #Psychedelics #The New England Journal of Medicine #Treatment-resistant depression #Trial data

Study shows ‘magic mushrooms’ could treat depression 

Psilocybin, a psychedelic derived from mushrooms, has been proven effective as a therapy for treatment-resistant depression (TRD) in the largest study of its kind.  The results of COMPASS Pathways’ Phase IIb trial have been published in The New England Journal of Medicine (NEJM). Read More

#News #Trending News

Brain inflammation
#Alzheimer's #Brain disease #Neurodegenerative disorders #Neuroinflammation #Neurology #Parkinson's

Covid-19 triggers inflammation in the brain

Research led by The University of Queensland has found that Covid-19 activates the same inflammatory response in the brain as Parkinson’s disease.  The discovery identified a potential future risk for neurodegenerative conditions in people who have had Covid-19, but also a possible treatment.  The UQ… Read More

#Covid-19 #News

Neurons in the brain
#Antidepressants #Interview #Major depressive disorder #Neuropsychiatric disorders #Neuroscience #Precision medicine #Precision psychiatry #Psychiatry

Precision psychiatry: Transforming therapeutics for CNS disorders

Mike McCully, CEO of Gate Neurosciences, speaks to DDW’s Diana Spencer about the company’s pipeline of next-generation antidepressants and why this could be the most exciting time in the history of psychiatry. DS: How has our understanding of the brain developed in the last 70 years?  MM: Although our… Read More

#Exclusive Content

#AI #Artificial intelligence (AI) #Brain disease #Nervous system disorders #Neuroscience #Neurotechnology

Keeping technology at the front of neuroscience research 

Listen to this article on the DDW Podcast: David Gray, CSO of Inscopix talks to Lu Rahman about the company’s understanding of the neuroscience market and its quest to improve technologies for neuroscientists to enable multimodal research.  Inscopix is a neurotechnology… Read More

#Exclusive Content

#AI #Biopharmaceuticals #Collaboration #Neuroscience #Psychiatry #Therapeutics

Collaboration extended in severe neuropsychiatric disorders 

Clinical-stage biopharmaceutical company Karuna Therapeutics has extended its drug discovery collaboration with PsychoGenics, AI-enabled phenotypic drug discovery and preclinical CRO services.  The collaboration aims to identify potential novel drug candidates for the treatment of severe neuropsychiatric disorders.  The initial multi-year agreement, announced in July 2020,… Read More

#News

Tau proteins
#Alzheimer's #Cognitive impairment #Dementia #Tau protein

Study reveals new therapeutic target in neurodegenerative disease

Early-cognitive decline may result from a shift in the ratio of a protein sub-type in our brain cells triggering cell-loss, according to a new study. The discovery, published in Scientific Reports, provides a new therapeutic target to prevent the onset of neurodegenerative diseases including dementia and Alzheimer’s. It is the… Read More

#News

#ALS #Alzheimer's #Biomarkers #Breast cancer #Cell and gene therapy #Head and neck cancer #Ice Bucket Challenge #Manufacturing #Neurodegenerative disorders #Oncology #Ophthalmology

This week in drug discovery (3-7 October)

News round-up for 3-7 October by DDW Digital Content Editor Diana Spencer This week has brought new trial results and regulatory approvals shedding light and bringing hope into therapy areas of unmet need. The University of Birmingham and… Read More

#News

Jigsaw puzzle of the brain
#Alzheimer's #Antibody #Clinical trial #Cognitive impairment #Drug development #Drug discovery #Phase III trial

New Alzheimer’s treatment reduces decline in Phase III trial

A new Alzheimer’s disease (AD) treatment has been shown to reduce clinical decline in mild cognitive impairment (MCI) due to AD and mild AD with confirmed presence of amyloid pathology in the brain.  Eisai and Biogen’s anti-amyloid beta (Aβ) protofibril antibody lecanemab met the primary endpoint and… Read More

#News

#Alzheimer's #Drug discovery #Inherited tauopathies #Neurodegenerative disorders #Neuroscience #Tau protein

Taking a new approach to tackle neurodegenerative diseases

Listen to this article on the DDW Podcast: William Erhardt, President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases.  New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on… Read More

#Editor's Choice #Exclusive Content

Ice Bucket Challenge
#ALS #Drug discovery #FDA #Fundraising #Ice Bucket Challenge #The ALS Association

‘Ice Bucket Challenge’ funds FDA-approved ALS treatment

The US Food and Drug Administration (FDA) has granted approval to AMX0035, a new treatment for people living with amyotrophic lateral sclerosis (ALS). Development of the drug was funded by $2.2 million from the ALS Association, raised by the 2014 social media craze the ‘Ice Bucket Challenge’. Another… Read More

#News #Regulatory #Trending News

Neurons
#FDA #Gene therapy #Neurodegenerative disorders

FDA approves gene therapy for rare neurological disorder

SKYSONA has become the first FDA approved therapy to slow the progression of neurologic dysfunction in boys with cerebral adrenoleukodystrophy (CALD). The US Food and Drug Administration (FDA) has granted Accelerated Approval to bluebird bio’s SKYSONA (elivaldogene autotemcel), also known as eli-cel, in boys four to 17 years of age… Read More

#News #Regulatory

#Alzheimer's #Cancer research #Colorectal cancer #Drug discovery #Eczema #FDA #Plaque Psoriasis

This week in drug discovery (12-16 September)

News round-up for 12-16 September by DDW Digital Content Editor Diana Spencer A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time. … Read More

#News

CT scans of the brain
#Alzheimer's #Cognitive impairment #Drug discovery #US patent

Potential Alzheimer’s drug receives US patent

The United States Patent Office (USPTO) has issued a patent covering drug candidate ACD856, which is currently being developed to treat Alzheimer’s disease and other disorders with cognitive impairment. ACD856 is part of AlzeCure Pharma’s NeuroRestore platform, which it is hoped could provide treatments for Alzheimer’s, Parkinson’s disease and depression. Read More

#News